keyword
MENU ▼
Read by QxMD icon Read
search

Macular oedema

keyword
https://www.readbyqxmd.com/read/27913439/retinitis-pigmentosa-associated-cystoid-macular-oedema-pathogenesis-and-avenues-of-intervention
#1
REVIEW
S Strong, G Liew, M Michaelides
Hereditary retinal diseases are now the leading cause of blindness certification in the working age population (age 16-64 years) in England and Wales, of which retinitis pigmentosa (RP) is the most common disorder. RP may be complicated by cystoid macular oedema (CMO), causing a reduction of central vision. The underlying pathogenesis of RP-associated CMO (RP-CMO) remains uncertain, however, several mechanisms have been proposed, including: (1) breakdown of the blood-retinal barrier, (2) failure (or dysfunction) of the pumping mechanism in the retinal pigment epithelial, (3) Müller cell oedema and dysfunction, (4) antiretinal antibodies and (5) vitreous traction...
December 2, 2016: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/27911446/treatment-patterns-of-ranibizumab-intravitreal-injection-and-dexamethasone-intravitreal-implant-for-retinal-vein-occlusion-in-the-usa
#2
S Nghiem-Buffet, S Baillif, S Regnier, A Skelly, N Yu, A Sodi
PurposeRanibizumab, an anti-vascular endothelial growth factor, and dexamethasone, a corticosteroid, have been shown to be effective in treating macular oedema secondary to retinal vein occlusion (RVO) (central RVO (CRVO) and branch RVO (BRVO)). Their real-world usage, however, has yet to be compared. We therefore evaluated ophthalmology visits for both drugs using US patient-level data.MethodsThe IMS Health Real-World Data Medical Claims database was used to identify treatment-naive patients receiving ranibizumab intravitreal injections or dexamethasone intravitreal implants between June 2010 and February 2014 who had 12 months of follow-up data...
December 2, 2016: Eye
https://www.readbyqxmd.com/read/27896896/presumed-tuberculous-uveitis-in-non-endemic-country-for-tuberculosis-case-series-from-a-new-zealand-tertiary-uveitis-clinic
#3
Ken K Ng, Mitzi Nisbet, Erika M Damato, Joanne L Sims
BACKGROUND: To describe the clinical spectrum of presumed tuberculous (TB) uveitis in a developed, non-endemic country of high immigrant population. DESIGN: Retrospective review of a consecutive case series. PARTICIPANTS: All 39 patients diagnosed with presumed TB uveitis at the tertiary uveitis service in Auckland from 2007 to 2014. METHODS: Clinical chart review. MAIN OUTCOME MEASURES: Patient demographics, risk factors, ophthalmic manifestations, management and outcome...
November 28, 2016: Clinical & Experimental Ophthalmology
https://www.readbyqxmd.com/read/27894518/radiation-maculopathy-treated-with-intravitreal-bevacizumab
#4
J L Sánchez-Vicente, A Muñoz-Morales, M P Galván-Carrasco, A Castilla-Lázpita, C Vital-Berral, A Alfaro-Juárez, T Rueda-Rueda
CASE REPORT: A 47 year-old woman with a choroidal melanoma developed a macular oedema secondary to radiation therapy 75 months after brachytherapy plaque. The patient received 3 intravitreal Bevacizumab injections. DISCUSSION: The patient had a good response to bevacizumab treatment. In fact, there was a reduction in the macular oedema measured by optical coherence tomography (OCT) scan, as well as an improvement in best corrected visual acuity. There was no recurrence of macular oedema, and visual acuity remained stable after 3-years follow-up...
November 25, 2016: Archivos de la Sociedad Española de Oftalmología
https://www.readbyqxmd.com/read/27888183/long-term-visual-and-systemic-prognoses-of-83-cases-of-biopsy-proven-sarcoid-uveitis
#5
Cédric Rochepeau, Yvan Jamilloux, Sebastien Kerever, Camille Febvay, Laurent Perard, Christiane Broussolle, Carole Burillon, Laurent Kodjikian, Pascal Seve
AIMS: To determine the long-term visual and systemic outcomes of uveitis patients with biopsy-proven sarcoidosis. METHODS: A retrospective study of biopsy-proven sarcoid uveitis, with a 3-year minimum follow-up, seen at Lyon University Hospital, between April 2004 and January 2016. RESULTS: A total of 83 patients were included, with a median age at onset of 52 (37-62) years and an unbalanced gender ratio (women 77.1%). Thirty-one patients had original systemic sarcoidosis in addition to ocular localisation, whereas 52 initially presented with isolated sarcoid uveitis...
November 25, 2016: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/27886183/fingolimod-therapeutic-mechanisms-and-ocular-adverse-effects
#6
REVIEW
P Mandal, A Gupta, W Fusi-Rubiano, P A Keane, Y Yang
Fingolimod is an oral immunomodulating drug used in the management of relapsing-remitting multiple sclerosis (RRMS). We aim to review the published literature on ocular manifestations of fingolimod therapy and their possible underlying mechanisms. The therapeutic effects of fingolimod are mediated via sphingosine receptors, which are found ubiquitously in various organs, including lymphoid cells, central nervous system, cardiac myocytes, and smooth muscle cells. Fingolimod-associated macular oedema (FAME) is the most common ocular side effect but retinal haemorrhages and retinal vein occlusion can occur...
November 25, 2016: Eye
https://www.readbyqxmd.com/read/27885039/th17-cell-frequency-and-il-17a-concentrations-in-peripheral-blood-mononuclear-cells-and-vitreous-fluid-from-patients-with-diabetic-retinopathy
#7
Hui Chen, Xiangrong Ren, Nanying Liao, Feng Wen
OBJECTIVE: To quantify T helper (Th)17 cells and determine interleukin (IL)-17A levels in peripheral blood mononuclear cell (PBMC) culture and vitreous fluid from patients with type 2 diabetes mellitus (T2DM) with diabetic retinopathy (DR). METHODS: Th17 cell frequency and IL-17A concentrations in PBMCs from 60 patients with T2DM with DR, 30 without DR and 30 sex- and age-matched healthy individuals were measured by flow cytometry and enzyme-linked immunosorbent assay (ELISA), respectively...
November 24, 2016: Journal of International Medical Research
https://www.readbyqxmd.com/read/27874278/placental-growth-factor-and-its-potential-role-in-diabetic-retinopathy-and-other-ocular-neovascular-diseases
#8
REVIEW
Quan Dong Nguyen, Sandro De Falco, Francine Behar-Cohen, Wai-Ching Lam, Xuri Li, Nadine Reichhart, Federico Ricci, Jennifer Pluim, William W Li
The role of vascular endothelial growth factor (VEGF), including in retinal vascular diseases, has been well studied, and pharmacological blockade of VEGF is the gold standard of treatment for neovascular age-related macular degeneration, retinal vein occlusion and diabetic macular oedema. Placental growth factor (PGF, previously known as PlGF), a homologue of VEGF, is a multifunctional peptide associated with angiogenesis-dependent pathologies in the eye and non-ocular conditions. Animal studies using genetic modification and pharmacological treatment have demonstrated a mechanistic role for PGF in pathological angiogenesis...
November 22, 2016: Acta Ophthalmologica
https://www.readbyqxmd.com/read/27833450/the-era-of-anti-vascular-endothelial-growth-factor-vegf-drugs-in-ophthalmology-vegf-and-anti-vegf-therapy
#9
REVIEW
Dorota Pożarowska, Piotr Pożarowski
Angiogenesis is a clue process for tissue development and function, both in normal and pathological conditions. This process is regulated by multiple molecular systems. One of the most potent is vascular endothelial growth factor (VEGF) and its receptor (VEGFR) system. Members of this family are involved in new vessel formation in embryogenesis and maturation, as well as in reparative or pathological reactions in later stages. They play a substantial role in regeneration, inflammation, wound healing, as well as in cancer pathology...
2016: Central-European Journal of Immunology
https://www.readbyqxmd.com/read/27815455/the-correction-of-aphakia-using-anterior-chamber-intraocular-lens
#10
REVIEW
Marilita M Moschos, Eirini Nitoda
Senile cataract is the leading cause of severe vision loss and blindness worldwide, affecting approximately 20 million people. Anterior chamber intraocular lens (AC IOLs) remain a surgical option for visual rehabilitation required after surgical extraction of the cataract lens. Relevant publications in the PUBMED database were searched for articles regarding the types, visual outcomes and the complications followed the surgical implantation of AC IOLs. AC IOLs, which can be iris- (iris-claw) or angle-supported, increase visual acuity in most patients...
November 2016: In Vivo
https://www.readbyqxmd.com/read/27801522/prophylactic-non-steroidal-anti-inflammatory-drugs-for-the-prevention-of-macular-oedema-after-cataract-surgery
#11
REVIEW
Blanche X Lim, Chris Hl Lim, Dawn K Lim, Jennifer R Evans, Catey Bunce, Richard Wormald
BACKGROUND: Macular oedema (MO) is the accumulation of extracellular fluid in the central retina (the macula). It may occur after cataract surgery and may give rise to poor visual outcome, with reduced visual acuity and distortion of the central vision. MO is often self-limiting with spontaneous resolution, but a small proportion of people with chronic persistent MO may be difficult to treat. Chronic oedema may lead to the formation of cystic spaces in the retina termed 'cystoid macular oedema' (CMO)...
November 1, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27778454/quantification-of-fluid-resorption-from-diabetic-macular-oedema-with-foveal-serous-detachment-after-dexamethasone-intravitreal-implant-ozurdex-%C3%A2-in-a-pregnant-diabetic
#12
Delila Hodzic-Hadzibegovic, Shakoor Ba-Ali, Marianne Valerius, Henrik Lund-Andersen
PURPOSE: To quantify the fluid resorption from the centre of the fovea in a pregnant woman with diabetic macular oedema by daily optical coherence tomography (OCT) measurements after the administration of intravitreal dexamethasone implant (Ozurdex(®) ). METHODS: A 36-year-old pregnant woman with type 1 diabetes for 33 years presented with diabetic macular oedema with foveal serous detachment and symptomatic vision loss at 16 gestational weeks. Best-corrected visual acuity (BCVA) in Snellen notation and central retinal volume assessed by optical coherence tomography (OCT, Topcon Corporation) were measured almost on a daily basis the first five weeks after implantation and then 2-3 times per month until childbirth...
October 24, 2016: Acta Ophthalmologica
https://www.readbyqxmd.com/read/27775223/imaging-retinal-inflammatory-biomarkers-after-intravitreal-steroid-and-anti-vegf-treatment-in-diabetic-macular-oedema
#13
Stela Vujosevic, Tommaso Torresin, Silvia Bini, Enrica Convento, Elisabetta Pilotto, Raffaele Parrozzani, Edoardo Midena
PURPOSE: To evaluate changes of specific retinal imaging biomarkers [intraretinal hyper-reflective retinal spots: HRS ; subfoveal neuroretinal detachment: SND; and increased foveal autofluorescence: IFAF after intravitreal steroid or anti-vascular endothelial growth factor treatment in diabetic macular oedema (DME)] as possible indicators of retinal inflammatory condition. METHODS: Retrospective analysis of images and clinical charts of 49 eyes (49 patients) with DME treated with intravitreal dexamethasone (dexamethasone, 23 eyes) or intravitreal ranibizumab (ranibizumab, 26 eyes)...
October 24, 2016: Acta Ophthalmologica
https://www.readbyqxmd.com/read/27773491/papillophlebitis-versus-paediatric-venous-thrombosis-a-case-with-46c-t-polymorphism-in-the-f12-coagulation-gene
#14
A Gargallo-Benedicto, M Cerdà-Ibáñez, Á Olate-Pérez, R Clemente-Tomás, I Almor Palacios, J M Hervás Hernandis, A Duch-Samper
CLINICAL CASE: An 8 year-old boy with no known diseases, with sudden loss of visual acuity (VA) in the left eye (LE). EXAMINATION: VA 1 in right eye, and 0.1 in LE, discrete left relative afferent pupil defect (RAPD). Normal biomicroscopy. Funduscopy: congestive papilla, venous tortuosity, peripapillary haemorrhages with macular oedema in LE. The systemic study only revealed A C46Tpolymorphism in the F12 coagulation gene. He had a VA of 1 and normal funduscopy 8 months later...
October 20, 2016: Archivos de la Sociedad Española de Oftalmología
https://www.readbyqxmd.com/read/27757552/safety-and-tolerability-of-fingolimod-in-patients-with-relapsing-remitting-multiple-sclerosis-results-of-an-open-label-clinical-trial-in-italy
#15
Alice Laroni, Davide Brogi, Vincenzo Brescia Morra, Leonello Guidi, Carlo Pozzilli, Giancarlo Comi, Alessandra Lugaresi, Renato Turrini, Debora Raimondi, Antonio Uccelli, Giovanni Luigi Mancardi
: The safety profile of fingolimod is well established in clinical trials and post-marketing studies. This study aimed to evaluate the safety and tolerability of fingolimod in a cohort of Italian patients with relapsing-remitting multiple sclerosis (RRMS). This is a non-comparative, open-label, multicentre, interventional study conducted in patients with RRMS with no suitable alternative treatment option. Safety and tolerability of fingolimod 0.5 mg were assessed by recording adverse events (AEs) and serious AEs (SAEs)...
October 18, 2016: Neurological Sciences
https://www.readbyqxmd.com/read/27730316/alemtuzumab-induced-remission-of-multiple-sclerosis-associated-uveitis
#16
Mark D Willis, Trevor P Pickersgill, Neil P Robertson, Richard W J Lee, Andrew D Dick, Ester Carreño
PURPOSE: The purpose of the study was to report a case of multiple sclerosis (MS)-associated uveitis refractory to conventional immunosuppressants, with subsequent remission following treatment with alemtuzumab. METHODS: Case report Patient was treated with intravenous alemtuzumab, a lymphocyte depleting anti-CD52 monoclonal antibody that has recently been approved for use in relapsing MS. RESULTS: A 17-year-old female presented with bilateral optic neuritis and subsequently bilateral intermediate uveitis and secondary macular oedema...
October 11, 2016: International Ophthalmology
https://www.readbyqxmd.com/read/27721789/treatment-of-retinitis-pigmentosa-associated-cystoid-macular-oedema-using-intravitreal-aflibercept-eylea-despite-minimal-response-to-ranibizumab-lucentis-a-case-report
#17
Stacey A Strong, Avinash Gurbaxani, Michel Michaelides
BACKGROUND: We present an interesting case of bilateral retinitis pigmentosa (RP)-associated cystoid macular oedema that responded on two separate occasions to intravitreal injections of aflibercept, despite previously demonstrating only minimal response to intravitreal ranibizumab. This unique case would support a trial of intravitreal aflibercept for the treatment of RP-associated cystoid macular oedema. CASE PRESENTATION: A 38-year-old man from Dubai, United Arab Emirates, presented to the UK with a 3-year history of bilateral RP-associated cystoid macular oedema...
May 2016: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/27661663/management-of-macular-oedema-in-diabetic-patients-undergoing-cataract-surgery
#18
Francesco Boscia, Ermete Giancipoli, Giuseppe D'Amico Ricci, Antonio Pinna
PURPOSE OF REVIEW: The aim of this study was to describe all the treatment modalities used to prevent and manage macular oedema in diabetic patients undergoing cataract surgery. RECENT FINDINGS: Topical NSAIDs have been proposed to be an effective strategy to prevent postsurgical macular oedema (PME) in diabetic patients. The prophylactic use of intravitreal antivascular endothelial growth factors (anti-VEGF) drugs and steroids in these patients, even if effective, brings some concerns with regard to possible side effects...
January 2017: Current Opinion in Ophthalmology
https://www.readbyqxmd.com/read/27635062/prevalence-and-predictors-of-metamorphopsia-after-successful-rhegmatogenous-retinal-detachment-surgery-a-cross-sectional-comparative-study
#19
Chuandi Zhou, Qiurong Lin, Fenge Chen
AIMS: To evaluate the prevalence of metamorphopsia after successful rhegmatogenous retinal detachment (RRD) surgery and determine the independent predictors of metamorphopsia. METHODS: A cross-sectional, comparative study. The study included 380 eyes of 357 patients who underwent a successful RRD surgery between 2009 and 2015. The presence of metamorphopsia was tested with an Amsler grid and the foveal microstructure was scanned with high-resolution spectral-domain optical coherence tomography (OCT) at a follow-up visit...
September 15, 2016: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/27625164/morphological-and-functional-changes-in-recalcitrant-diabetic-macular-oedema-after-intravitreal-dexamethasone-implant
#20
Pierluigi Iacono, Maurizio Battaglia Parodi, Matteo Scaramuzzi, Francesco Bandello
BACKGROUND: To evaluate the effects of dexamethasone implant in eyes affected by recalcitrant diabetic macular oedema (DME) associated with proliferative diabetic retinopathy (PDR). METHODS: Thirteen consecutive patients with centre-involving DME associated with PDR, central macular thickness (CMT) ≥300 µm, previous therapy with panretinal photocoagulation, focal/grid laser treatment and anti-vascular endothelial growth factor injection were prospectively enrolled...
September 13, 2016: British Journal of Ophthalmology
keyword
keyword
102386
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"